期刊
BLOOD
卷 118, 期 25, 页码 6649-6659出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2011-03-339978
关键词
-
类别
资金
- Lundbeck Foundation
- Danish Cancer Society
- Novo Nordisk Foundation
- Danish Medical Research Council
- Swedish Research Council
- Lundbeck Foundation [R17-2007-1726] Funding Source: researchfish
Smad4 is important in the TGF-beta pathway and required for transcriptional activation and inhibition of cell growth after TGF-beta 1 stimulation. We demonstrate that miR-130a is differentially expressed during granulopoiesis and targets Smad4 mRNA. The transcript for Smad4 is present throughout neutrophil maturation, but Smad4 protein is undetectable in the most immature cells, where miR-130a is highly expressed. Two miR-130a binding sites were identified in the 3'-untranslated region of the Smad4 mRNA. Overexpression of miR-130a in HEK293, A549, and 32Dcl3 cells repressed synthesis of Smad4 protein without affecting Smad4 mRNA level. Repression of Smad4 synthesis in a granulocytic cell line by miR-130a reduced its sensitivity to TGF-beta 1-induced growth inhibition. This effect was reversed by inhibiting the activity of miR-130a with an antisense probe or by expressing a Smad4 mRNA lacking miR-130a binding sites. High endogenous miR-130a and Smad4 mRNA levels and low expression of Smad4 protein were found in the t(8;21)(q22;q22) acute myelogenous leukemia-derived cell line Kasumi-1. When miR-130a was inhibited by an antisense RNA, the amount of Smad4 protein increased in Kasumi-1 cells and rendered it susceptible for TGF-beta 1-mediated cell growth inhibition. Our data indicate that miR-130a is involved in cell cycle regulation of granulocytic cells through engagement of Smad4 in the TGF-beta pathway. (Blood. 2011;118(25):6649-6659)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据